Curated News
By: NewsRamp Editorial Staff
August 17, 2026

Quantum BioPharma Cuts Costs, Advances Lucid-MS to Phase 2

Discuss on SubstackDiscuss on TelegramParticipate in discussion on BlueskyParticipate in discussion on MastodonView history of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma cuts expenses 53% while advancing Lucid-MS to Phase 2, boosting its competitive edge in MS treatment.
  • Quantum BioPharma reduced Q2 operating costs to $2.29M and secured FDA approval for its IND application for Lucid-MS Phase 2 trial.
  • Quantum BioPharma's FDA-approved Phase 2 trial for Lucid-MS brings hope for progressive MS patients by potentially reversing myelin damage.
  • Quantum BioPharma's cash reserves doubled to $9.5M, and its Lucid-MS could reverse myelin degradation, a key MS mechanism.

Impact - Why it Matters

This news matters because Quantum BioPharma's FDA approval for Lucid-MS Phase 2 trial represents a significant step toward a potential new treatment for progressive multiple sclerosis, a condition with limited therapeutic options. The company's improved financial health and reduced burn rate increase its ability to fund critical clinical development, potentially impacting patients' lives and the biotech investment landscape.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has announced its second-quarter 2026 financial results, showcasing a significant reduction in operating expenses by 53% year-over-year to $2.29 million, and a 47% decrease in general and administrative expenses to $1.76 million. The company's cash position has strengthened, with combined cash, cash equivalents, and digital assets totaling approximately $9.5 million as of June 30, up from $4.1 million at the end of 2025. Management states that current liquidity is sufficient to fund planned operations to at least October 2027, assuming the first-half 2026 cash burn rate continues.

In a major development, the FDA approved Quantum's Investigational New Drug (IND) application for Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation, which is the underlying mechanism of multiple sclerosis. This approval clears the way for a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis. Lucid-MS is developed through Quantum's wholly-owned subsidiary, Lucid Psycheceuticals Inc. The company also retains a 19.84% stake in Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC version of UNBUZZD(TM), and is entitled to royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity.

Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company's focus on Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis, a condition affecting millions worldwide. With the FDA's IND approval, Quantum is poised to advance its lead candidate into clinical trials, bringing hope to patients with progressive MS. The company's improved financial position and reduced expenses demonstrate prudent management, positioning it well for future development. For more details, investors can view the full press release at https://nnw.fm/dlAAe and access the company's newsroom at https://ibn.fm/QNTM.

Source Statement

This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Quantum BioPharma Cuts Costs, Advances Lucid-MS to Phase 2

Blockchain registration record for this content